Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
Immunostimulatory agents used in cancer treatment often elicit serious toxicities, limiting their clinical application. Here, the authors show that the use of liposomes to intravenously deliver surface-anchored IL-2 and anti-CD137 proteins enables anti-cancer immunity and reduces the toxic side effe...
Saved in:
Main Authors: | Yuan Zhang, Na Li, Heikyung Suh, Darrell J. Irvine |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/3d4040a0e60d452b9cad0c19ca4f203c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
by: Marta Compte, et al.
Published: (2018) -
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
by: Daniela Schmid, et al.
Published: (2017) -
Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response
by: Xiang Yu, et al.
Published: (2020) -
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
by: Daniel S. Leventhal, et al.
Published: (2020) -
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
by: Dobrin Draganov, et al.
Published: (2021)